Interações de Budesonida + formoterol

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (bula de Abiraterona, Advertências e precauções)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Adalimumabe, Advertência em caixa preta)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Inhaled beta agonist: salmeterol ↑ salmeterol Coadministration of salmeterol with REYATAZ is not recommended. (bula de Atazanavir, Interações medicamentosas)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (bula de Axitinibe, Advertências e precauções)

…intubation (endotracheal) 1 2 Asthma-related hospitalization (≥24-hour stay) 115 105 ICS = Inhaled Corticosteroid, LABA = Long-acting Beta2-adrenergic Agonist The pediatric safety trial included 6208 pediatric patients 4 to 11 years of age who received ICS/LABA (fluticasone propionate /salmeterol inhalation powder) or ICS (fluticasone propionate inhalation powder). (bula de Budesonida + formoterol, Advertências e precauções)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Baricitinibe, Advertência em caixa preta)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Paradoxical Bronchospasm and Upper Airway Symptoms As with other inhaled medications, budesonide and formoterol fumarate dihydrate can produce paradoxical bronchospasm, which may be life threatening. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (bula de Cetoconazol, Interações medicamentosas)

Known Hypersensitivity or Idiosyncrasy to the Sympathomimetic Amines NUMBRINO is contraindicated in patients with a known history of hypersensitivity to cocaine or to the components of the nasal solution. (bula de Cocaína, Advertências e precauções)

Inhaled beta agonist : salmeterol ↑ salmeterol Co-administration of salmeterol and PREZISTA/ritonavir is not recommended. (bula de Darunavir, Interações medicamentosas)

Inhaled beta agonist: salmeterol ↑ salmeterol Co-administration with salmeterol is not recommended and may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia. (bula de Darunavir + cobicistate, Interações medicamentosas)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (bula de Docetaxel, Advertências e precauções)

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (bula de Dronabinol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Inhaled Beta Agonist: salmeterol ↑ salmeterol Coadministration of salmeterol and GENVOYA is not recommended. (bula de Elvitegravir + cobicistate + entricitabina + tenofovir, Interações medicamentosas)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (bula de Entricitabina + rilpivirina + tenofovir, Contraindicações)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Etanercepte, Advertência em caixa preta)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS ). (bula de Fenelzina, Contraindicações)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

…intubation (endotracheal) 1 2 Asthma-related hospitalization (≥24-hour stay) 115 105 ICS = Inhaled Corticosteroid, LABA = Long-acting Beta2-adrenergic Agonist The pediatric safety trial included 6208 pediatric patients 4 to 11 years of age who received ICS/LABA (fluticasone propionate /salmeterol inhalation powder) or ICS (fluticasone propionate inhalation powder). (bula de Budesonida + formoterol, Advertências e precauções)

Serious Asthma-Related Events – Hospitalizations, Intubations and Death Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART) ]. (bula de Budesonida + formoterol, Advertências e precauções)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Inhaled beta-agonist: Salmeterol ↑ Salmeterol Concurrent administration of salmeterol with fosamprenavir calcium is not recommended. (bula de Fosamprenavir, Interações medicamentosas)

Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (bula de Imipramina, Interações medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Infliximabe, Advertência em caixa preta)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (bula de Levotiroxina + liotironina, Advertência em caixa preta)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (bula de Liotironina, Advertência em caixa preta)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (bula de Lovastatina, Contraindicações)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (bula de Mifepristona, Advertência em caixa preta)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (bula de Mitotano, Advertência em caixa preta)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (bula de Moexipril, Advertências)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (bula de Ribavirina, Advertência em caixa preta)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (bula de Rilpivirina, Contraindicações)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Serious Asthma-Related Events – Hospitalizations, Intubations and Death Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART) ]. (bula de Budesonida + formoterol, Advertências e precauções)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (bula de Sirolimo, Advertências e precauções)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (bula de Budesonida + formoterol, Advertências e precauções)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (bula de Somatropina, Interações medicamentosas)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Tocilizumabe, Advertência em caixa preta)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Tofacitinibe, Advertência em caixa preta)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (bula de Trandolapril, Advertências)

…(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. (bula de Tranilcipromina, Advertência em caixa preta)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (bula de Tretinoína, Advertência em caixa preta)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (bula de Trióxido de arsênio, Advertência em caixa preta)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Upadacitinibe, Advertência em caixa preta)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (bula de Budesonida + formoterol, Advertências e precauções)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

The chance is higher if you are age 60 or older take a blood thinning (anticoagulant) or steroid drug have 3 or more alcoholic drinks every day while using this product have had stomach ulcers or bleeding problems take more or for a longer time than directed take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others]… (bula de Ácido acetilsalicílico, Advertências)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (bula de Ácido mefenâmico, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (bula de Ácido zoledrônico, Advertências e precauções)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (bula de Aclidínio, Interações medicamentosas)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (bula de Afatinibe, Advertências e precauções)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (bula de Albendazol, Advertências e precauções)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (bula de Alendronato, Advertências e precauções)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (bula de Alentuzumabe, Advertências e precauções)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (bula de Alisquireno, Advertências e precauções)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (bula de Alogliptina + metformina, Interações medicamentosas)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (bula de Alpelisibe, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (bula de Anfotericina B, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Albuterol (or other beta 2 agonists): Increase the frequency of monitoring blood pressure and heart rate. (bula de Atomoxetina, Interações medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (bula de Aztreonam, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Beladona + ópio, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (bula de Bendamustina, Advertências e precauções)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (bula de Benralizumabe, Advertências e precauções)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (bula de Bictegravir + entricitabina + tenofovir alafenamida, Interações medicamentosas)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (bula de Bortezomibe, Advertências e precauções)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Buprenorfina, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Buprenorfina + naloxona, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Butorfanol, Advertências)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (bula de Cefoxitina, Advertências e precauções)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Celecoxibe, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (bula de Cetamina, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (bula de Cetoprofeno, Advertências e precauções)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (bula de Cetorolaco, Advertências e precauções)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (bula de Ciprofloxacino, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (bula de Citarabina, Advertências)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Codeína, Advertências e precauções)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (bula de Daptomicina, Advertências e precauções)

Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive… (bula de Deferasirox, Interações medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (bula de Denosumabe, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

Sex hormone binding globulins are increased and result in elevated levels of total circulating sex steroids however, free or biologically active levels either decrease or remain unchanged. e. (bula de Desogestrel + etinilestradiol, Precauções)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

The amount of both steroids should be considered in the choice of an oral contraceptive. (bula de Diacetato de etinodiol + etinilestradiol, Advertências)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (bula de Dicicloverina, Interações medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Diclofenaco, Advertências e precauções)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Diclofenaco + misoprostol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (bula de Diflunisal, Advertências)

Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (bula de Digoxina, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (bula de Doxapram, Interações medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (bula de Dupilumabe, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (bula de Erlotinibe, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. (bula de Estradiol, Precauções)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins [see Warnings and Precautions ( 5.11 ) and Drug Interactions ( 7.2 )]. (bula de Estradiol + dienogeste, Interações medicamentosas)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (bula de Estradiol + noretisterona, Advertências e precauções)

Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), SHBG, leading to increased total circulating corticosteroids and sex steroids respectively. (bula de Estrogênios conjugados, Precauções)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (bula de Estrogênios conjugados + bazedoxifeno, Advertências e precauções)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (bula de Etodolaco, Advertências)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (bula de Etravirina, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (bula de Fenilacetato de sódio + benzoato de sódio, Interações medicamentosas)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (bula de Fenilbutirato de glicerol, Interações medicamentosas)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (bula de Fenilbutirato de sódio, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Fenoprofeno, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Fentanila, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (bula de Fingolimode, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (bula de Flurbiprofeno, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (bula de Glimepirida, Interações medicamentosas)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (bula de Glipizida, Interações medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (bula de Haloperidol, Interações medicamentosas)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (bula de Hidralazina, Advertências)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Hidrocodona, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Hidrocodona + homatropina, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Hidrocodona + ibuprofeno, Advertências)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Hidrocodona + paracetamol, Advertências)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Hidromorfona, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (bula de Ibandronato, Advertências e precauções)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Ibuprofeno, Advertências e precauções)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Ibuprofeno + famotidina, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Indometacina, Advertências e precauções)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (bula de Insulina asparte, Interações medicamentosas)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (bula de Insulina degludeca, Interações medicamentosas)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (bula de Insulina detemir, Interações medicamentosas)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (bula de Insulina glargina, Interações medicamentosas)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (bula de Insulina lispro, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (bula de Ivermectina, Advertências)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (bula de Levofloxacino, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy Clinical effect Concomitant use of CHCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin [see Warnings and Precautions (5.11) ]. (bula de Levonorgestrel + etinilestradiol, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Levorfanol, Advertências)

Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (bula de Levotiroxina, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (bula de Margetuximabe, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (bula de Medroxiprogesterona, Advertências e precauções)

Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (bula de Megestrol, Advertências e precauções)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Meloxicam, Advertências e precauções)

Decrease corticosteroids gradually, if appropriate. (bula de Mepolizumabe, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Metadona, Advertências e precauções)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (bula de Metazolamida, Interações medicamentosas)

If not, corticosteroids may be given and other causes of anemia should be considered. (bula de Metildopa, Advertências)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (bula de Metiltestosterona, Advertências)

This can be corrected by giving appropriate doses of corticosteroids. (bula de Metirapona, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (bula de Metotrexato, Interações medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Inhaled corticosteroid may be reduced gradually. (bula de Montelucaste, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Morfina, Advertências e precauções)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (bula de Moxifloxacino, Advertências e precauções)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (bula de Nabumetona, Advertências)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Nalbufina, Advertências)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Naproxeno, Advertências e precauções)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Naproxeno + esomeprazol, Advertências e precauções)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (bula de Natalizumabe, Advertências e precauções)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (bula de Nateglinida, Interações medicamentosas)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (bula de Nintedanibe, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (bula de Ocrelizumabe, Advertências e precauções)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (bula de Ofloxacino, Advertências)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Oliceridina, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (bula de Omalizumabe, Advertências e precauções)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Oxaprozina, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Oxicodona, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Oxicodona + paracetamol, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Oximorfona, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (bula de Pamidronato, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Paracetamol + codeína, Advertências)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Paracetamol + ibuprofeno, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (bula de Penicilamina, Advertências)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Pentazocina + naloxona, Advertências)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Petidina (meperidina), Advertências e precauções)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (bula de Pioglitazona + glimepirida, Interações medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Piroxicam, Advertências e precauções)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (bula de Ponesimode, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. (bula de Budesonida + formoterol, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (bula de Budesonida + formoterol, Interações medicamentosas)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (bula de Propofol, Advertências e precauções)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

…Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (bula de Rifampicina, Interações medicamentosas)

…Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (bula de Rifapentina, Interações medicamentosas)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (bula de Risedronato, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (bula de Rocurônio, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (bula de Salsalato, Advertências)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (bula de Sulindaco, Advertências)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (bula de Sumatriptana + naproxeno, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (bula de Suxametônio (succinilcolina), Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Tapentadol, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (bula de Temozolomida, Advertências e precauções)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (bula de Tensirolimo, Advertências e precauções)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (bula de Teofilina, Advertências)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (bula de Teriparatida, Advertências e precauções)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (bula de Tesamorrelina, Interações medicamentosas)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (bula de Testosterona, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Beta-blockers: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (bula de Tiotrópio, Interações medicamentosas)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (bula de Tolcapona, Interações medicamentosas)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (bula de Tolmetina, Advertências)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Tramadol, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Tramadol + paracetamol, Advertências e precauções)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (bula de Trastuzumabe, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [ see Boxed Warning ]. (bula de Varfarina, Interações medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (bula de Budesonida + formoterol, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (bula de Zanamivir, Advertências e precauções)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (bula de Zenocutuzumabe, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (bula de Acarbose, Interações medicamentosas)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (bula de Ácido bempedoico, Advertências e precauções)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (bula de Alteplase, Advertências e precauções)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (bula de Amicacina, Advertências e precauções)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (bula de Budesonida + formoterol, Advertências e precauções)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (bula de Ampicilina, Advertências)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (bula de Benzilpenicilina (penicilina G), Advertências)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (bula de Bevacizumabe, Advertências e precauções)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (bula de Bussulfano, Advertências)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (bula de Calcitriol, Interações medicamentosas)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefaclor, Advertências)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefadroxila, Advertências e precauções)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefdinir, Advertências)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefotetana, Advertências)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefprozila, Advertências)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Ceftazidima, Advertências)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (bula de Ceftriaxona, Advertências e precauções)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (bula de Clofarabina, Advertências e precauções)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (bula de Clomifeno, Advertências)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (bula de Budesonida + formoterol, Advertências e precauções)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (bula de Corticotropina, Advertências e precauções)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (bula de Dapagliflozina + metformina, Interações medicamentosas)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (bula de Droperidol, Interações medicamentosas)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (bula de Drospirenona + etinilestradiol, Advertências e precauções)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (bula de Budesonida + formoterol, Advertências e precauções)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (bula de Empagliflozina + metformina, Interações medicamentosas)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (bula de Etonogestrel + etinilestradiol, Interações medicamentosas)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (bula de Fenoximetilpenicilina (penicilina V), Advertências)

Steroids may or may not be effective in controlling these hemolytic episodes. (bula de Fludarabina, Advertências e precauções)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (bula de Glibenclamida, Interações medicamentosas)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (bula de Glibenclamida + metformina, Interações medicamentosas)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (bula de Glipizida + metformina, Precauções)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (bula de Glucagon, Advertências e precauções)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (bula de Guselcumabe, Advertências e precauções)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (bula de Insulina regular (humana), Advertências e precauções)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (bula de Budesonida + formoterol, Advertências e precauções)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (bula de Lenalidomida, Advertências e precauções)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (bula de Linagliptina + metformina, Interações medicamentosas)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (bula de Melfalana, Advertências)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (bula de Metformina, Interações medicamentosas)

Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (bula de Metoexital, Advertências)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (bula de Budesonida + formoterol, Advertências e precauções)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (bula de Mitoxantrona, Interações medicamentosas)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (bula de Naltrexona, Advertências e precauções)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (bula de Norelgestromina + etinilestradiol, Interações medicamentosas)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (bula de Noretisterona + etinilestradiol, Advertências e precauções)

Interactions with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (bula de Norgestimato + etinilestradiol, Interações medicamentosas)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (bula de Norgestrel + etinilestradiol, Precauções)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (bula de Oxacilina, Advertências)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (bula de Pioglitazona + metformina, Interações medicamentosas)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (bula de Propiltiouracila, Advertências)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (bula de Quinina, Interações medicamentosas)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (bula de Raloxifeno, Interações medicamentosas)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (bula de Repaglinida, Interações medicamentosas)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (bula de Rituximabe, Advertências e precauções)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (bula de Saxagliptina + metformina, Interações medicamentosas)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (bula de Sitagliptina + metformina, Interações medicamentosas)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (bula de Tenecteplase, Advertências e precauções)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (bula de Tiamazol (metimazol), Advertências)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (bula de Budesonida + formoterol, Advertências e precauções)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (bula de Ustequinumabe, Advertências e precauções)

Corticosteroides como a prednisona reduzem a absorção de cálcio e prejudicam o metabolismo da vitamina D, contribuindo para a perda óssea. (NIH Office of Dietary Supplements, Vitamin D)

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (bula de Budesonida + formoterol, Advertências e precauções)

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (bula de Budesonida + formoterol, Advertências e precauções)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (bula de Ziprasidona, Advertências e precauções)